Skip to main content
SpringerLink
Log in

Autres traitements pour le lymphome hodgkinien (LH) après la première rechute

  • Chapter
Actualités thérapeutiques dans les lymphomes

  • 545 Accesses

Résumé

En oncologie médicale, plus les maladies rechutent plus les chances de guérison diminuent et c’est le cas pour le LH. Environ 50 % des patients en première rechute vont guérir de leur maladie, mais en deuxième rechute ce taux est très faible même si certains patients peuvent vivre longtemps avec leur maladie.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Milpied N, Fielding AK, Pearce RM, et al. (1996) Allogeneic bone-marrow transplant is not better than autologous for patients with relapsed HD from the EBMT. J Clin Oncol 14: 1291–6

    PubMed  CAS  Google Scholar 

  2. Anderlini P, Saliba R, Acholonu S, et al. (2005) Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin’s disease: low transplant related mortality and impact of intensity of conditioning regimen. Bone Marrow Transplant 35: 943–51

    Article  PubMed  CAS  Google Scholar 

  3. Armand P, Kim HT, Ho VT, et al. (2008) Allogenic transplantation with RIC conditioning for Hodgkin and non-hodgkin lymphoma, importance of histology for outcome. Biol Blood and Marrow Tranplant 14: 418–25

    Article  CAS  Google Scholar 

  4. Peggs KA, Anderlini P, Sureda A (2008) Allogeneic transplantation for Hodgkin lymphoma. Brit J Hematol 143: 468–80

    Google Scholar 

  5. Sureda A, Robinson S, Canals C, et al. (2008) RIC conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin’s lymphoma, an analysis from the lymphoma working party of the EBMT. J Clin Oncol 26: 455–62

    Article  PubMed  CAS  Google Scholar 

  6. Robinson SP, Sureda A, Canals C, et al. (2009) RIC allogeneic stem cell transplantation for HL: identification of prognostic factors predicting outcome. Haematologica 94: 230–8

    Article  PubMed  Google Scholar 

  7. Thomson KJ, Peggs KS, Smith P, et al (2008) Superiority of RIC allogeneic transplantation over conventional treatment for relapse of HL following ASCT. Bone Marr Transplant 41: 765–70

    Article  CAS  Google Scholar 

  8. Sarina B, Castagna L, Farina L, et al. (2010) Allogeneic transplantation improves the overall and progression-free survival of HL patients relapsing after autologous transplantation. Blood 115: 3671–7

    Article  PubMed  CAS  Google Scholar 

  9. Sureda A, Canais C, Arranz R, et al. (2012) Allogeneic stem cell transplantation after RIC in patients with relapsed and refractory HL. Haematologica 97: 310–7

    Article  PubMed  Google Scholar 

  10. Brice P (2008) Managing relapsed and refractory Hodgkin lymphoma. B J Haematol 141: 3–13

    Article  Google Scholar 

  11. Santoro A, Bredenfeld L, Devizzi L, et al. (2000) Gemcitabine in the treatment of refractory Hodgkin’s disease: results of a multicenter phase II study. J Clin Oncol 18: 2615–9

    PubMed  CAS  Google Scholar 

  12. Bartlett NL, Niedzwiecki D, Johnson JL, et al. (2007) Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin’s lymphoma: CALGB 59804. Ann Oncol 18: 1071–9

    Article  PubMed  CAS  Google Scholar 

  13. Santoro A, Magagnoli M, Spina M, et al. (2007) Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin’s lymphoma. Haematologica 92: 35–41

    Article  PubMed  CAS  Google Scholar 

  14. Moskowitz AJ, Hamlin Jr PA, Gerecitano J, et al. (2009) Bendamustine is highly active in heavily pre-treated relapsed and refractory Hodgkin lymphoma and serves as a bridge to allogeneic stem cell transplant. ASH annual meeting

    Google Scholar 

  15. Jona A, Younes A (2010) Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma. Blood Rev 24: 233–8

    Article  PubMed  Google Scholar 

  16. Younes A, Pro B, Fayad L (2006) Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma. Blood 107: 1731–2

    Article  PubMed  CAS  Google Scholar 

  17. Fehniger TA, Larson S, Trinkaus K, et al. (2011) A phase 2 multicenter study of lenalidomide in relapsed refractory classical HL. Blood 118: 5119–25

    Article  PubMed  CAS  Google Scholar 

  18. Johnston PB, Inwards DJ, Colgan JP, et al. (2010) A phase II of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol

    Google Scholar 

  19. Younes A, Bartlett NL, Leonard JP, et al. (2010) Brentuximab vedotin (SGN35) for relapsed CD30-positive Lymphomas. N Engl J Med 363: 1812

    Article  PubMed  CAS  Google Scholar 

  20. Younes A, Gopal AK, Smith SE, et al. (2012) Results of a pivotal phase II study of brentuximab vedotin for relapsed or refractory Hodgkin’s Lymphoma. J Clin Oncol published on line March 26

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service d’hémato-oncologie, hôpital Saint-Louis, 1, avenue Claude Vellefaux, 75010, Paris, France

    P. Brice

Authors
  1. P. Brice
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P. Brice .

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag Paris

About this chapter

Cite this chapter

Brice, P. (2013). Autres traitements pour le lymphome hodgkinien (LH) après la première rechute. In: Actualités thérapeutiques dans les lymphomes. Springer, Paris. https://doi.org/10.1007/978-2-8178-0371-5_4

Download citation

  • DOI: https://doi.org/10.1007/978-2-8178-0371-5_4

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-8178-0370-8

  • Online ISBN: 978-2-8178-0371-5

Publish with us

Policies and ethics

Search

Navigation